Sugi Predict

Sugi Predict / Compounds / SCHEMBL2112349

SCHEMBL2112349

SCHEMBL2112349

CC(C)(C)OC(=O)n1cc(Br)c2ccncc21

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 1/20 0.40
▸ MARK3 P27448 1/20 0.40
▸ MAP4K2 Q12851 1/20 0.40
▸ CAMK2B Q13554 1/20 0.40
▸ PIM3 Q86V86 1/20 0.40
▸ PIM2 Q9P1W9 1/20 0.40
▸ ELANE P08246 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ HTR6 P50406 1/20 0.38
▸ GPR119 Q8TDV5 6/20 0.37
▸ BCHE P06276 1/20 0.37
▸ GBA1 P04062 1/20 0.35
▸ KDM5A P29375 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31330259 1.00 PIM1 (0.40) PIM1MARK3MAP4K2CAMK2BPIM3
SCHEMBL1710746 0.89 PIM1 (0.42) PIM1MARK3MAP4K2CAMK2BPIM3
SCHEMBL3228084 0.85 L3MBTL1 (0.43) PIM1MARK3MAP4K2CAMK2BPIM3
SCHEMBL31407790 0.84 PIM1 (0.40) PIM1MARK3MAP4K2CAMK2BPIM3
SCHEMBL3755156 0.84 PIM1 (0.40) PIM1MARK3MAP4K2CAMK2BPIM3
SCHEMBL29951804 0.83 L3MBTL1 (0.41) PIM1MARK3MAP4K2CAMK2BPIM3
SCHEMBL661642 0.83 L3MBTL1 (0.41) PIM1MARK3MAP4K2CAMK2BPIM3
SCHEMBL30940053 0.82 MEN1 (0.41) PIM1MARK3MAP4K2CAMK2BPIM3
SCHEMBL13079979 0.82 L3MBTL1 (0.51) PIM1MARK3MAP4K2CAMK2BPIM3
SCHEMBL13079977 0.82 MEN1 (0.41) PIM1MARK3MAP4K2CAMK2BPIM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4027995-B1 HPK1 ANTAGONISTS AND USES THEREOF NIMBUS SATURN INC (US) 2026-05-27 — — EP disclosed
US-12215105-B2 HPK1 antagonists and uses thereof Nimbus Saturn, Inc. (US) 2025-02-04 — — US disclosed
CN-112867715-B 5-azaindazole derivatives as adenosine receptor antagonists 默克专利股份公司 2024-03-05 — — CN disclosed
WO-2024044757-A1 AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS Sanford Burnham Prebys Medical Discovery Institute (US) 2024-02-29 — — WO disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 — — US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 — — US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 — — US disclosed
EP-3870582-B1 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2023-07-19 — — EP disclosed
EP-4182320-A1 INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS Nido Biosciences, Inc. (US) 2023-05-24 — — EP disclosed
CN-115996926-A Indole compounds as androgen receptor modulators 尼多生物科学有限公司 2023-04-21 — — CN disclosed
US-20210078997-A1 SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-03-18 — — US disclosed
WO-2020223306-A1 PIM KINASE INHIBITOR COMPOSITIONS AND USES THEREOF SNAP BIO, INC. (US) 2020-11-05 — — WO disclosed
US-8158625-B2 Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use GENENTECH, INC. (US) 2012-04-17 — — US disclosed
US-8158625-B2 Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use GENENTECH, INC. (US) 2012-04-17 — — US disclosed
US-8158625-B2 Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use GENENTECH, INC. (US) 2012-04-17 — — US disclosed
US-20100305084-A1 BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE HOFFMAN-LA ROCHE INC. 2010-12-02 — — US disclosed
US-20100305084-A1 BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE HOFFMAN-LA ROCHE INC. 2010-12-02 — — US disclosed
US-20100305084-A1 BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE HOFFMAN-LA ROCHE INC. 2010-12-02 — — US disclosed
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 — — US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305084-A1 BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE PI4K2B, PIK3CA, PIK3R2 PIM1 2863/4885MARK3 3392/4885MAP4K2 1256/4885
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 PIM1 2034/4885MARK3 400/4885MAP4K2 102/4885
US-20210078997-A1 SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS HIPK1, PDXK, IP6K1 PIM1 1896/4885MARK3 358/4885MAP4K2 73/4885
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 PIM1 464/4885MARK3 468/4885MAP4K2 3/4885
US-12215105-B2 HPK1 antagonists and uses thereof PDXK, HIPK1, PCK1 PIM1 2034/4885MARK3 400/4885MAP4K2 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.